Ocular Therapeutix Q2 2026 net loss $78.8M; AXPAXLI NDA on track for Q4 2026

OCULAR THERAPEUTIX, INC

Net loss of $78.8M ($0.35 per share) for Q2 2026, vs. $67.8M loss in Q2 2025.
Cash balance $598.6M as of June 30, 2026; expected runway into 2028.
AXPAXLI NDA submission for wet AMD planned for Q4 2026 after FDA Type C meeting alignment.
Post-hoc SOL-1 analysis shows up to 72% reduction in treatment burden vs. aflibercept (2 mg) over 60 weeks.
DEXTENZA revenue flat at $13.5M; R&D expenses $54.1M, up from $51.1M in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.